---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-019494"
form_type: "8-K"
ticker: "CODX"
cik: "0001692415"
company_name: "Co-Diagnostics, Inc."
filed_at: "2021-08-12T23:59:59+00:00"
generated_at: "2026-06-29T13:19:13.804210+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Co-Diagnostics reports Q2 revenue of $27.4M, EPS $0.33; guides Q3 revenue $23-25M

## Summary
- Revenue $27.4M (+13.8% YoY); net income $9.8M ($0.33 diluted EPS) vs $15.0M ($0.51) in Q2 2020.
- Gross profit margin 90.8% ($24.9M); operating income $11.8M (-19.8% YoY) due to higher R&D and sales commissions.
- Cash and marketable securities $72.4M as of June 30; operating cash flow YTD $24.7M.
- Q3 guidance: revenue $23-25M, diluted EPS $0.19-$0.22, effective tax rate ~19%, shares ~30M.
- Over 20M tests sold to-date; CE-mark for Logix Smart Direct Saliva test; new international CoPrimer patent.

## SEC filing metadata
- accession: 0001493152-21-019494
- form_type: 8-K
- ticker: CODX
- cik: 0001692415
- company_name: Co-Diagnostics, Inc.
- filed_at: 2021-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1692415/000149315221019494/0001493152-21-019494-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1692415/000149315221019494/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-019494
- JSON: https://secwatch.observer/filing/0001493152-21-019494.json
- Plain text: https://secwatch.observer/filing/0001493152-21-019494.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.